Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06455917 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

Study acronym: BaseTIL-02L
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Dec 2025 to Jan 22, 2025
    • Interventions: Combination of TIL Transfer and low dose IL-2 (Drug) to TILs（Tumor Infiltrating Lymphocytes） (Drug)
    • Study description expanded, about 69 words
    • Study site revised
  2. Start date: Jul 2024 to Dec 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT06455917
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)
Related terms Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov